Afya (NASDAQ: AFYA): Shares of Brazil’s Leading Medical Education Group Struggle to Breakout

Thanks to steady acquisitions, Bertelsmann backed Afya (NASDAQ: AFYAis a leading medical education and digital health services group in Brazil based on number of medical school seats – delivering an end-to-end physician-centric ecosystem. Since late 2021, shares have struggled to breakout beyond the $16 a share level.

(Note: You may need to have VPN set to North America to access their website…)


  • Afya is a leading medical education group in Brazil based on number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering digital products to help doctors enhance their healthcare services through their whole career.


Afya Limited Announces First-Quarter 2023 Financial Results and Webcast Presentation

  • Message from Management: “…This quarter was marked by significant increases in net revenue within our three segments and we are delighted to see that the most significant growth came from our Continue Education segment with a robust intake process, six new campuses, and course maturation.
  • Our second most significant growth came from our core business, as we saw higher tickets in Medicine courses, maturation of medical seats, the beginning of 4 Mais Médicos campuses, consolidation of UNIT Alagoas and FITS Jaboatão dos Guararapes acquisition, and the consolidation of 92 new medical seats, 28 in the UniSL Ji-Paraná campus, located in Rondônia, and 64 in Faculdade Santo Agostinho, in the city of Itabuna, situated in the state of Bahia.
  • And, once again, Afya reported great results on the Digital Health Services revenue, which ended the quarter with an increase of 20% when compared to last year. This result reinforces the opportunity ahead in Digital Services, and it is explained by the ramp-up in B2B engagements, with new contracts with the pharmaceutical industry companies, and the continuous ramp-up in B2P contracts, as we will discuss further on…”

Bertelsmann Completes Increase of Stake in Afya (Press Release)

  • Afya Limited, or Afya (Nasdaq: AFYA), further to the press releases issued by the Company on March 7, 2022 and April 25, 2022, today announced the closing of the transaction where Bertelsmann SE& Co. KGaA, or “Bertelsmann” acquired 6,000,000 Class B common shares of Afya at the purchase price of US$26.90 per share, from Nicolau Carvalho Esteves, Rosângela de Oliveira Tavares Esteves and NRE Capital Ventures Ltd (together with Nicolau Carvalho Esteves and Rosângela de Oliveira Tavares Esteves, the “Esteves Family”). As a result of the closing of the transaction, Bertelsmann and the Esteves family will beneficially own ~57.5% and ~33.0% voting interest, and ~31.0% and ~18.0% of the total shares, respectively, in Afya.
  • Bertelsmann is a media, services and education company that operates in about 50 countries around the world. It includes the entertainment group RTL Group, the trade book publisher Penguin Random House, the music company BMG, the service provider Arvato, the Bertelsmann Printing Group, the Bertelsmann Education Group and Bertelsmann Investments, an international network of funds. The company has around 130,000 employees and generated revenues of €17.3 billion in the 2020 financial year.

#TradeTalks: How the leading medical education group in Brazil is facing the #COVID19 pandemic (YouTube) 8:08 Minutes (Nasdaq) May 2020

  • Afya CEO Virgilio Gibbon joins Jill Malandrino on Nasdaq #TradeTalks to discuss how the leading medical education group in Brazil is facing the #COVID19 pandemic.

Behind the Bell: AFYA (YouTube) 10:05 Minutes (Nasdaq) July 2019



Finviz Chart




Subscribe Now Via Substack

IR Afya

Disclaimer. The information and views contained on this website and newsletter is provided for informational purposes only and does not constitute investment advice and/or a recommendation. Your use of any content is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the content. Seek a duly licensed professional for any investment advice. I may have positions in the investments covered. This is not a recommendation to buy or sell any investment mentioned.

Similar Posts:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Visit Us On TwitterVisit Us On FacebookVisit Us On LinkedinCheck Our FeedVisit Us On Instagram